계명대학교 의학도서관 Repository

Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer

Metadata Downloads
Author(s)
Changhoon YooSung-Bae KimJungsil RoSeock-Ah ImYoung-Hyuck ImJee Hyun KimJin-Hee AhnKyung Hae JungHong Suk SongSeok Yun KangHee Sook ParkHyun-Cheol Chung
Keimyung Author(s)
Song, Hong Suk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Research and Treatment
Issued Date
2016
Volume
48
Issue
2
Keyword
TSU-68Breast neoplasmsAngiogenesisBiological markersPharmacology
Abstract
Purpose
This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial
comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast
cancer.
Materials and Methods
A total of 77 patients were eligible for this study (38!in the TSU-68 plus docetaxel arm and
39 in the docetaxel alone arm). Blood samples were collected prior to the start of each
cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-
AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6)
levels were measured using enzyme linked immunosorbent assay. The primary endpoint
was progression-free survival (PFS).
Results
In patients with baseline PDGF-AA " median, median PFS was significantly worse in the TSU-
68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months,
p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGFAA
< median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68
plus docetaxel group, PFS showed significant association with fold changes in CRP
(p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment
cycle.
Conclusion
Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive
for the efficacy of TSU-68.
Keimyung Author(s)(Kor)
송홍석
Publisher
School of Medicine
Citation
Changhoon Yoo et al. (2016). Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer. Cancer Research and Treatment, 48(2), 499–507. doi: 10.4143/crt.2015.089
Type
Article
ISSN
1598-2998
DOI
10.4143/crt.2015.089
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33150
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.